COMPUGROUP MED. NA O.N./ DE000A288904 /
27/06/2024 22:58:39 | Diferencia -0.220 | Volumen | Bid22:58:39 | Ask22:58:39 | Capitalización de mecado | Dividendo A. | P/E Ratio |
---|---|---|---|---|---|---|---|
24.660EUR | -0.88% | - Volumen de negocios: - |
24.660Volumen de oferta: - | 24.840Tamaño/ Volumen/ Formato de Ask: - | 1.28 mil millonesEUR | 4.07% | 27.95 |
GlobeNewswire
2:51
isandisofx.com Celebrates Major Milestones at 2023 Annual Summary Meeting in Cape Town
GlobeNewswire
2:48
LAKESIDE HOLDING LIMITED ANNOUNCES PRICING OF $6.75 MILLION INITIAL PUBLIC OFFERING
GlobeNewswire
2:22
CFIUS Approval Obtained for the Planned Merger of North American Stainless, Inc. and Haynes Internat...
GlobeNewswire
2:00
ROSEN, THE FIRST FILING FIRM, Encourages FutureFuel Corp. Investors to Secure Counsel Before Importa...
GlobeNewswire
1:51
ROSEN, LEADING INVESTOR COUNSEL, Encourages Gritstone bio, Inc. Investors to Secure Counsel Before I...
GlobeNewswire
1:39
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
GlobeNewswire
1:31
PATH INVESTOR ALERT: Edelson Lechtzin LLP Urges UiPath, Inc. (NYSE: PATH) Shareholders to Consult Le...
GlobeNewswire
1:30
ROSEN, A LEADING LAW FIRM, Encourages Charge Enterprises, Inc. Investors to Secure Counsel Before Im...
GlobeNewswire
1:17
TMCF President and CEO Dr. Harry L. Williams has released the following statement on the FY25 House ...
GlobeNewswire
1:15
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fastly, Inc. Investors to Secure Counsel Before Importan...
GlobeNewswire
1:10
Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
GlobeNewswire
1:00
Worldwide License Agreement for EA1080, Oral Selective α4β7 Integrin Antagonist, Signed between EA P...
GlobeNewswire
0:30
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determinatio...
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página